NOVARTIS PHARMACEUTICALS UK LTD (WT) - WT2024-11, WT2024-12, WT2024-13 - RIBOCICLIB [KISQALI] (AS SUCCINATE) 200 mg Tablets, SECUKINUMAB (COSENTYX) 150 mg in 1mL & 300 mg in 2mLInjections

Concepts

• pharmaceutical products
• londonderry
• wt2024
• novartis pharmaceuticals uk ltd
• wt2024-11
• wt2024-13 - ribociclib
• ribociclib
• wt2024-12
• - ribociclib
• 300 mg

Location

Northern Ireland:

Geochart for 1 buyers and 1 suppliers

Western Health & Social Care Trust

Novartis Pharmaceuticals

+−

Leaflet | Map tiles by Stamen Design, under CC BY 3.0. Data by OpenStreetMap, under ODbL.

Description

Supply of RIBOCICLIB [KISQALI] (AS SUCCINATE) 200 mg Tablets to meet clinical need in the Western Trust until 15/08/2027. Supply of SECUKINUMAB (COSENTYX) 150 mg in 1mL & 300mg in 2mL Injections to meet clinical need in the Western Trust until 03/08/2025.

Award Detail

Award Criteria

CPV Codes

• 33600000 - Pharmaceutical products

Legal Justification

Regulation 32(2)(b)iii permits the award of a public contract by a negotiated procedure without prior publication where the works, supplies or services can only be supplied by a particular economic operator due to the protection of exclusive rights, including intellectual property rights. The absence of competition is not the result of an artificial narrowing down of the parameters of the procurement. The Western Health and Social Care Trust requires the purchase of RIBOCICLIB [KISQALI] (AS SUCCINATE) 200 mg Tablets, SECUKINUMAB (COSENTYX) 150 mg in 1mL & 300 mg in 2mLInjections which are subject to patent protection / Sole MA Holder and consequently no reasonable alternative of substitute exists.

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. **